Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
CMNDVancouver, Canada, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement
CMNDVancouver, Canada, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
CMNDVancouver, Canada, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of patient enrollment for the second cohort in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). The cohort consists of six patients, who were recruited rapidly across three premier clinical sites: Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
CMNDVancouver, Canada, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, announced today that on December 4, 2025, the Company received a written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company’s closing bid price for its common shares was below $1.00 per share for the last 30 consecutive business days.
Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder
CMNDVancouver, Canada, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced another key milestone in its Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD): the first participant has been enrolled and dosed with CMND-100, its proprietary MEAI-based oral drug candidate, at Hadassah-University Medical Center in Jerusalem, Israel.
Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
CMNDVancouver, Canada, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced positive top-line results from the first cohort of its Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder (AUD).
Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
CMNDVancouver, Canada, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of an Israeli patent application for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing depression.
Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
CMNDVancouver, Canada, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company developing therapies for central nervous system disorders.
Clearmind Medicine Engages Government And Political Affairs Firm To Advance Psychedelic Therapeutics And Regulatory Advocacy
CMNDClearmind Medicine Enrolls First Patient In Phase I/IIa Clinical Trial For CMND-100, Proprietary MEAI-Based Oral Drug Candidate Aimed At Treating Alcohol Use Disorder
CMNDSciSparc Announced That Its Collaboration With Clearmind Medicine Has Led To The Publication Of A European Patent Application By The European Patent Office
CMNDSciSparc, Clearmind Collaboration Leads To Filing Of International Patent Application For Proprietary Treatment Targeting Anorexia, Bulimia And Other Eating Disorders
CMNDClearmind Medicine Files A International Patent Application For The Novel Treatment Of Anorexia, Bulimia And Other Eating Disorders
CMNDClearmind Medicine Announces Initiation of Alcohol Use Disorder Phase I/IIa Clinical Trial At All Current Clinical Sites
CMNDClearmind Medicine Unveils First U.S. Clinical Site For FDA-Approved Clinical Trial To Investigate Full Pharmacokinetic Profile Of CMND-100, In Alcohol Use Disorder Patients
CMNDClearmind Medicine Initiates Phase I/IIa Clinical Trial At Its First U.S. Clinical Site, Johns Hopkins University School Of Medicine
CMNDClearmind Medicine Announced The Publication Of An International Patent Application In Collaboration With Yissum Research Development Company Of The Hebrew University Of Jerusalem, The Patent Application Covers Psychedelic-based Compounds For Mental Healt
CMNDClearmind Launches EDC System To Support Phase I/II Clinical Trial Of MEAI-Based Treatment
CMNDClearmind Medicine's FDA-Approved Clinical Trial For CMND-100 Arrives In U.S.
CMNDClearmind Medicine Announced That It Has Signed A Non-binding Letter Of Intent With Polyrizon To Develop A Novel Intranasal Formulation For Its Psychedelic-based Treatment Applications
CMNDSciSparc Shares Are Soaring Monday: What's Going On?
CMNDSciSparc Ltd (NASDAQ:SPRC) shares are ripping higher Monday after the company announced that its collaboration with Clearmind Medicine Inc (NASDAQ:CMND) led to a patent application for psychedelic therapy targeting cocaine addiction.
SciSparc and Clearmind Secure South Korean Patent for Innovative Cocaine Addiction Treatment
CMNDClearmind Wins South Korea Patent for Psychedelic Therapy Targeting Cocaine Addiction
CMNDWhy Is Penny Stock Clearmind Gaining Today?
CMNDClearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol use disorder.
Clearmind Medicine Secures IRB Approval For Alcohol Use Disorder Trial At Yale
CMND